Home / Business and Economy / Swiss AI Firm Atlast Bio Secures $12.5M Funding

Swiss AI Firm Atlast Bio Secures $12.5M Funding

27 Oct

Summary

Swiss AI startup Atlast Bio focuses on virtual patient drug trials.
The company announced $12.5 million in new funding.
Swedish venture capital firm Creandum led the investment round.

Atlast Bio, a Swiss artificial intelligence startup, has announced the successful closure of a $12.5 million funding round. The company is at the forefront of developing novel drug trials using virtual patients, a method aimed at accelerating and refining the drug development process.

The significant investment was led by Creandum, a prominent Swedish venture capital firm with a notable history of supporting successful tech companies, including early investments in Spotify and Trade Republic. This funding is expected to fuel Atlast Bio's expansion and further its research in AI-driven pharmaceutical testing.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.